Showing results (1161-1170 of 1,193) with videos related to

Sort By:
Pageof 120
Journal of the National Comprehensive Cancer Network : JNCCN|April 16, 2013
Melanoma, version 2.2013: featured updates to the NCCN guidelinesDaniel G Coit, Robert Andtbacka, Christopher J Anker, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2021
Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanomaAlexander Mm Eggermont, Andrey Meshcheryakov, Victoria Atkinson, et al.
Nature|April 24, 2025
BMAL1-HIF2A heterodimer modulates circadian variations of myocardial injuryWei Ruan, Tao Li, In Hyuk Bang, et al.
Scientific Data|July 29, 2022
The University of Pennsylvania glioblastoma (UPenn-GBM) cohort: advanced MRI, clinical, genomics, & radiomicsSpyridon Bakas, Chiharu Sako, Hamed Akbari, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|May 10, 2014
Melanoma, version 4.2014Daniel G Coit, John A Thompson, Robert Andtbacka, et al.
Epidemiology and Infection|November 18, 2024
Increased measles and rubella seroprevalence in children using residual blood samples from health facilities and household serosurveys after supplementary immunization activities in two districts in IndiaChristine Prosperi, Alvira Z Hasan, Amy K Winter, et al.
Biorxiv : the Preprint Server for Biology|July 19, 2024
Cohesin-mediated 3D contacts tune enhancer-promoter regulationPhiline Guckelberger, Benjamin R Doughty, Glen Munson, et al.
Molecular Cell|July 7, 2015
Metabolic Rewiring by Oncogenic BRAF V600E Links Ketogenesis Pathway to BRAF-MEK1 SignalingHee-Bum Kang, Jun Fan, Ruiting Lin, et al.
The New England Journal of Medicine|September 12, 2017
Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV MelanomaJeffrey Weber, Mario Mandala, Michele Del Vecchio, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 7, 2019
Durable Tumor Regression and Overall Survival in Patients With Advanced Merkel Cell Carcinoma Receiving Pembrolizumab as First-Line TherapyPaul Nghiem, Shailender Bhatia, Evan J Lipson, et al.
Pageof 120